Sirio Pharma Management
Management criteria checks 3/4
Sirio Pharma's CEO is Peiqing Li, appointed in Apr 2015, has a tenure of 10.08 years. directly owns 9.14% of the company’s shares, worth CN¥644.81M. The average tenure of the management team and the board of directors is 10.1 years and 7 years respectively.
Key information
Peiqing Li
Chief executive officer
CN¥1.9m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.1yrs |
| CEO ownership | 9.1% |
| Management average tenure | 10.1yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
CEO
Peiqing Li (59 yo)
Mr. Peiqing Li has been Chairman of the Board and General Manager at Sirio Pharma Co., Ltd. since April 23, 2015.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 10.1yrs | CN¥1.91m | 9.14% CN¥ 644.8m | |
| CFO & Financial Director | 2.3yrs | CN¥2.66m | 0.011% CN¥ 777.6k | |
| Deputy GM & Director | 10.1yrs | CN¥1.71m | 5.57% CN¥ 392.9m | |
| Deputy General Manager | no data | CN¥1.29m | 0.10% CN¥ 7.1m |
Experienced Management: 300791's management team is seasoned and experienced (10.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Chairman of the Board | 10.1yrs | CN¥1.91m | 9.14% CN¥ 644.8m | |
| Deputy GM & Director | 10.1yrs | CN¥1.71m | 5.57% CN¥ 392.9m | |
| Director | 10.1yrs | CN¥164.90k | 3.24% CN¥ 228.3m | |
| Director | 10.1yrs | CN¥1.85m | 2.63% CN¥ 185.8m | |
| Independent Director | 3.8yrs | CN¥136.40k | no data | |
| Independent Director | 3.8yrs | CN¥157.40k | no data | |
| Independent Director | 3.8yrs | CN¥154.40k | no data | |
| Non-Employee Supervisor | 3.8yrs | no data | no data | |
| Chairman of the Supervisory Board | 10.1yrs | no data | no data | |
| Supervisor | 2.6yrs | no data | no data |
Experienced Board: 300791's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 09:41 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sirio Pharma Co., Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jing Huang | Chasing Securities |
| Wendan Wang | China International Capital Corporation Limited |
| Xia Sheng | Citic Securities Co., Ltd. |